Peptone was born out of 30 years of combined academic research into Intrinsically Disordered Proteins at Cambridge, Oxford, ETH Zurich and University of Groningen.
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
The focal point of our interdisciplinary team of researchers is intersection of physics, molecular biology and next-generation supercomputing.
We use highly sophisticated structural analysis techniques, such as nuclear magnetic resonance (NMR) spectroscopy and hydrogen-exchange mass spectrometry (HDX-MS), which can measure the physical properties of dynamic, disordered proteins as they move.
This data is then fed into Peptone’s supercomputer, which applies physical modeling methods and machine learning algorithms to create millions of simulations of the most likely conformations of a particular disordered protein or protein regions and the best way to target them with drugs. These predictions are then tested in the lab and the results are fed back in for further cycles of refinement, generating viable drug candidates to take forward for further development.
Our protein biophysics research facility is located in Bellinzona, Switzerland, with the company’s experimentalists and management based there.
Peptone’s theoretical and BD team sits at our corporate HQ in London, UK.
Peptone’s NVIDIA DGX A100 supercomputer is located at Verne Global’s data center campus in Keflavik, Iceland, where it runs on 100% renewable geothermal and hydroelectric energy.